End stage kidney disease is a global public health problem with an estimated 2.4 million patients on dialysis.
The number of new cases is rising (7-8% annually) due to population ageing and increased diabetes prevalence. The NEPHRON+ project is improving the lives of patients by developing a wearable artificial kidney device, enabled with information and communication technologies for remote monitoring.Chronic kidney disease will affect one in ten of us at some point in our lives. For those of us unlucky enough to suffer renal failure as a result, the health consequences can be disastrous.
Without treatment kidney failure is deadly. However, even the best treatments are not ideal. Patients have to be treated with a dialysis machine at home or in hospital, sometimes as often as once every four hours. Patients spend a large part of their lives connected to dialysis equipment. What’s more, the life expectancy of a person in their 20s who has suffered kidney failure is just 20 years, unless they’re lucky enough to receive a donated organ.
All this could change, however. An EU-funded research consortium has been developing a wearable artificial kidney that would make it possible for dialysis patients to lead a more full and active life while adding another 10 to 16 years to their life expectancy.
The future of wearable dialysis
The NEPHRON+ WAKD (Wearable Artificial Kidney Device) is currently undergoing animal trials and will have to pass several rounds of stringent tests in humans before it is ready to be used by all patients with kidney disease. However, the project has reached a stage where commercial partners are ready to take the technology to the next stage. With kidney failure rates on the rise and pressure on hospitals to find more cost effective and clinically effective treatments, the market for wearable dialysis devices could be worth as much as a €15 billion per year, according to Dr Leonidas Lymberopoulos, project coordinator.
The advantages of wearable dialysis
The NEPHRON+ system works like a conventional dialysis machine, taking the patient’s blood and passes it through a number of filters, removing waste products that would be excreted in a healthy patient’s urine and making sure that the patient’s blood pressure stays at a safe level. The patient can see the monitored data via their smartphone. What’s more, the data can be sent to the patient’s specialist doctor, so that their condition can be monitored at all times. But the wearable device will reduce the chance that a patient has to go to hospital for emergency treatment as constant dialysis is much more effective than intermittent treatment.
Frank Simonis, technical manager of NEPHRON+ explains: “Continuous, 24/7 dialysis with a wearable device offers a smooth and uniform extraction of toxins over the day similar to the natural kidney. This improves the health condition tremendously and eliminates the ‘after dialysis sickness syndrome’ that many patients suffer from.”
Dr Lymberopoulos suggests that the cost of caring for a patient with kidney disease will fall due to the reduction in the need for prescription medicine, nursing staff and installation costs. Cost savings in medical care are expected to €15.000-20.000/patient/year. With 340.000 patients in Europe this implies an annual saving of €5-7 billion.Most importantly, explains Ms Anastasia Garbi, former project leader, “the patient can now lead a more normal life, working and exercising without the regular long visits to the hemodialysis centers”.
The Latest on: Artificial kidney
via Google News
The Latest on: Artificial kidney
- Patients’ families prefer when dialysis is stopped before death or additional hospice services are providedon October 18, 2019 at 8:07 am
artificial nutrition and other life-sustaining interventions, can delay death but also raise ethically challenging questions about the value of life and whether and when to withhold or stop these ...
- New Artificial Pancreas Study: 'A Step Closer to a Brighter Future'on October 17, 2019 at 7:39 am
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), said in an NIH statement. The artificial pancreas is an all-in-one system that tracks blood glucose using a CGM and ...
- The robot that cuddles you to sleep: Kidney-shaped Somnox costs £549 and can 'banish insomnia'on October 17, 2019 at 5:37 am
The kidney-shaped sleeping buddy is able to slow down the users' breathing by simulating ... This data can be used to determine whether you are awake or in a deep sleep. The device's artificial ...
- Continuous Renal Replacement Therapy Market 2019 Industry Development and Growth Forecast to 2026on October 17, 2019 at 5:25 am
According to American Kidney Fund, in 2015, around 31 million people were diagnosed with chronic kidney disease and it is the ninth leading cause of death in the U.S. Moreover, an innovative ...
- Nephrology and Urology Devices Market 2019 Industry Development and Growth Forecast to 2026on October 17, 2019 at 5:25 am
Moreover, increasing healthcare expenditure in developed economies such as the U.S. and China is also expected to boost growth of the market. Significant advancements in wearable artificial kidney for ...
- RenalytixAI Partners with Capital District Physicians' Health Plan, Inc. on KidneyIntelX™on October 17, 2019 at 4:00 am
NEW YORK, Oct. 17, 2019 /PRNewswire/ -- Renalytix AI plc (AIM: RENX), a developer of artificial intelligence enabled clinical diagnostics for kidney disease, announces that Capital District Physicians ...
- Artificial pancreas system better controls blood glucose levels than current technologyon October 16, 2019 at 2:02 pm
The trial, based partly at the University of Virginia Center for Diabetes Technology, was primarily funded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), part of the ...
- Johns Hopkins nephrology director joins kidney disease startupon October 15, 2019 at 1:09 pm
Renalytix AI, a company that develops artificial intelligence-enabled clinical diagnostics for kidney diseases, named Baltimore-based Johns Hopkins Medicine's Chirag Parikh, MD, to its board. Three ...
- Johns Hopkins Director of Nephrology Chirag Parikh Joins RenalytixAI Boardon October 14, 2019 at 5:48 am
NEW YORK, Oct. 14, 2019 /PRNewswire/ -- Renalytix AI plc (AIM: RENX), a developer of artificial intelligence-enabled clinical diagnostics for kidney disease, announced today the appointment of leading ...
- Toxic chemicals are found in blades of artificial turfon October 10, 2019 at 5:04 pm
The test results showed that the turf contained elevated levels of per- and polyfluoroalkyl chemicals known as PFAS, which have been linked to kidney cancer, low infant birth weights, and a range of ...
via Bing News